⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 7, 2024Open Access

Supplementary Figure 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa Susan M. Geyer Andrew B. Nixon Federico Innocenti Qian Shi Priya Kumthekar Sawyer Jacobson Imane El Dika Amin Yaqubie Juan Lopez Binhui Huang Yi‐Wei Tang Yujia Wen Lawrence H. Schwartz Anthony B. El-Khoueiry Jennifer J. Knox Lakshmi Rajdev Monica M. Bertagnolli Jeffrey A. Meyerhardt Eileen M. O’Reilly Alan P. Venook

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 1. CONSORT diagram of those with evaluable sample for the HCV-based analyses for this manuscript

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abou‐Alfa et al. (2024) studied this question.

synapsesocial.com/papers/68e7556db6db6435876cd65b https://doi.org/10.1158/2767-9764.25359918

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024
2Supplementary Figure 4 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024
3Supplementary Figure 4 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024
4Supplementary Figure 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024
5Supplementary Figure 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024

More related papers

Supplementary Figure 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024
Supplementary Figure 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024
FIGURE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma2024